For p53-deficient CRPC, flubendazole is a well-known anti-malarial drug and a potential anti-tumor drug that has been shown to induce cell cycle arrest in the G2/M phase, promote cell death in vitro by inducing p53 expression, and inhibit the growth of CRPC tumors in xenograft models (98). The gene discussed is TP53; the disease is neoplasm.